Benitec Biopharma raises ~$30M in underwritten and direct common stock offering at $13/share

Benitec Biopharma Inc.

Underwritten offering of 1,143,000 shares and 300,000 pre-funded warrants at $13.00/$12.9999 per unit.
Concurrent registered direct offering of 900,000 shares to Averill funds (Suvretta affiliates) at same $13.00 price.
Gross proceeds ~$30M; net proceeds to fund product candidate development, working capital, and general corporate purposes.
Benitec discussed appointing David Friedman, managing director at Suvretta Capital, to the board, subject to approval.
Offering expected to close March 26, 2025; underwriters include Leerink Partners and TD Cowen as bookrunners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.